Proteasome inhibition overcomes the resistance of renal cell carcinoma cells against the PPARγ ligand troglitazone

Cellular and Molecular Life Sciences

Volumn 66, Issue 7, 2009, Pages 1295-1308

  Von Schwarzenberg, K ^a   Held, S A E ^a   Schaub, A ^b   Brauer, K M ^b   Bringmann, A ^a   Brossart, P ^a  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Apoptosis; PPAR ; Proteasome inhibition; Renal cell carcinoma; Signal pathways

Indexed keywords

BORTEZOMIB; CASPASE 3; GROWTH FACTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MITOGEN ACTIVATED PROTEIN KINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PROTEASOME; PROTEASOME INHIBITOR; TRANSCRIPTION FACTOR RELB; TROGLITAZONE;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CARCINOMA CELL; CELL ACTIVATION; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG SENSITIZATION; ENDOPLASMIC RETICULUM STRESS; ENZYME INHIBITION; GENE EXPRESSION; HUMAN; HUMAN CELL; INCUBATION TIME; KIDNEY CARCINOMA; NUCLEAR LOCALIZATION SIGNAL; PROTEIN LOCALIZATION; PROTEIN SECRETION; SENSITIVITY ANALYSIS;

ANGIOGENESIS INDUCING AGENTS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BORONIC ACIDS; CARCINOMA, RENAL CELL; CASPASE 3; CELL LINE, TUMOR; CHROMANS; CYTOKINES; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; ENDOPLASMIC RETICULUM; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; KIDNEY NEOPLASMS; MITOGEN-ACTIVATED PROTEIN KINASES; NF-KAPPA B; PPAR GAMMA; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; SIGNAL TRANSDUCTION; THIAZOLIDINEDIONES;

EID: 63449141174     PISSN: 1420682X     EISSN: 15691632     Source Type: Journal    
DOI: 10.1007/s00018-009-8542-7     Document Type: Article

References (58)

1. McLaughlin, J. K. and Lipworth, L. (2000) Epidemiologic aspects of renal cell cancer. Semin. Oncol. 27, 115-23.
2. Vogelzang, N. J. and Stadler, W. M. (1998) Kidney cancer. Lancet. 352, 1691-6.
3. Stenzl, A. and deKernion, J. B. (1989) Pathology, biology, and clinical staging of renal cell carcinoma. Semin. Oncol. 16, 3-11.
4. Bukowski, R. M. (1997) Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2. Cancer. 80, 1198-220.
5. Talks, K. L., Turley, H., Gatter, K. C., Maxwell, P. H., Pugh C. W., Ratcliffe, P. J., and Harris, A. L. (2000) The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumorassociated macrophages. Am. J. Pathol. 157, 411-21.
6. Yao M., Yoshida M., Kishida T., Nakaigawa N., Baba M., Kobayashi K., Miura T., Moriyama M., Nagashima Y., Nakatani Y., Kubota Y., and Kondo K. (2002) VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma. J. Natl. Cancer Inst. 94, 1569-75.
7. Ivan M, Kondo K, Yang H, Kim W, Valiando J, Ohh M, Salic A, Asara J. M., Lane WS, and Kaelin WG, Jr. (2001) HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for 02 sensing. Science. 292, 464-8.
8. Harris, A. L., (2002) Hypoxia -a key regulatory factor in tumour growth. Nat Rev Cancer. 2, 38-47.
9. Grandinetti, C. A., and Goldspiel, B, R., (2007) Sorafenib and sunitinib: novel targeted therapies for renal cell cancer. Pharmacotherapy. 27, 1125-44.
10. Hutson, T. E., and Figlin, R. A., (2007) Evolving role of novel targeted agents in renal cell carcinoma. Oncology (Williston Park). 21, 1175-80.
11. Hutson, T. E., and Figlin, R. A., (2007) Renal Cell Cancer. Cancer J. 13, 282-6.
12. Evans, R, M., (1988) The steroid and thyroid hormone receptor superfamily, Science. 240, 889-95.
13. Chinetti, G, Griglio, S, Antonucci, M, Torra, I. P., Delerive, P., Majd, Z., Fruchart J.C., Chapman J, Najib J, and Staels, B. (1998) Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages. J Biol Chem. 273, 25573-80.
14. Koeffler, H. P. (2003) Peroxisome proliferator-activated receptor gamma and cancers. Clin Cancer Res. 9, 1-9.
15. Mueller, E., Sarraf, P., Tontonoz, P., Evans, R. M., Martin, K. J., Zhang, M., Fletcher, C., Singer, S., and Spiegelman, B. M., (1998) Terminal differentiation of human breast cancer through PPAR gamma. Mol. Cell. 1, 465-70.
16. Shimada, T., Kojima, K., Yoshiura, K., Hiraishi, H., and Terano, A. (2002) Characteristics of the peroxisome proliferator activated receptor gamma (PPARgamma) ligand induced apoptosis in colon cancer cells. Gut. 50, 658-64.
17. Appel, S., Mirakaj, V., Bringmann, A., Weck, M. M., Grunebach, F., and Brossart, P. (2005) PPAR-gamma agonists inhibit toll-like receptor-mediated activation of dendritic cells via the MAP kinase and RF-kappaB pathways. Blood. 106, 3888-94.
18. Roccaro, A. M., Hideshima, T, Raje, N., Kumar, S., Ishitsuka, K., Yasui, H., Shiraishi, N., Ribatti, D., Nico, B., Vacca, A., Dammacco, F., Richardson, P. G., and Anderson, K. C. (2006) Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. Cancer Res. 66, 184-91.
19. Sunwoo, J. B., Chen, Z., Dong, G., Yeh, N., Crowl, B. C., Sausville, E., Adams, J., Elliott, P., and Van, W. C., (2001) Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin. Cancer Res. 7, 1419-28.
20. Demetri, G. D., Fletcher, C. D., Mueller, E., Sarraf, P., Naujoks, R., Campbell, N., Spiegelman, B. M., and Singer, S. (1999) Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma. Proc. Natl. Acad. Sci. U. S. A. 96, 3951-6.
21. Lehmann, J. M., Moore, L. B., Smith-Oliver, T. A., Wilkison, W.O., Willson, T. M., and Kliewer, S.A. (1995) An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J. Biol. Chem. 270, 12953-6.
22. Nencioni, A., Schwarzenberg, K., Brauer, K. M., Schmidt, S. M., Ballestrero, A., Grunebach, F., and Brossart, P. (2006) Proteasome inhibitor bortezomib modulates TLR4-induced dendritic cell activation. Blood. 108, 551-8.
23. Rao, R. V., Hermel, E., Castro-Obregon, S., del Rio, G., Ellerby, L. M., Ellerby, H. M., and Bredesen, D. E. (2001) Coupling endoplasmic reticulum stress to the cell death program. Mechanism of caspase activation. J. Biol. Chem. 276, 33869-74.
24. Weber, S. M., Chambers, K. T., Bensch, K. G., Scarim, A. L., and Corbett, J. A. (2004) PPARgamma ligands induce ER stress in pancreatic beta-cells: ER stress activation results in attenuation of cytokine signaling. Am. J. Physiol. Endocrinol. Metab. 287, E1171-E1177.
25. Rawrocki, S. T., Carew, J. S., Pino, M. S., Highshaw, R. A., Dunner, K. Jr., Huang, P., Abbruzzese, J. L., and McConkey, D. J. (2005) Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis. Cancer Res. 65, 11658-66.
26. Nicoletti, I., Migliorati, G., Pagliacci, M. C., Grignani, F. and Riccardi, C. (1991) A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J. Immunol. Methods. 139, 271-9.
27. Nencioni, A., Lauber, K., Grunebach, F., Brugger, W., Denzlinger, C., Wesselborg, S., and Brossart, P. (2002) Cyclopentenone prostaglandins induce caspase activation and apoptosis in dendritic cells by a PPAR-gamma-independent mechanism: regulation by inflammatory and T cell-derived stimuli. Exp. Hematol. 30, 1020-8.
28. Chow, J. C., Young, D. W., Golenbock, D. T., Christ, W. J., and Gusovsky, F. (1999) Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction. J. Biol. Chem. 274, 10689-92.
29. Nencioni A, Lauber K, Grunebach F, Brugger W, Denzlinger C, Wesselborg S, and Brossart P. (2002) Cyclopentenone prostaglandins induce caspase activation and apoptosis in dendritic cells by a PPAR-gamma-independent mechanism: regulation by inflammatory and T cell-derived stimuli. Exp Hematol. 30, 1020-8.
30. Nencioni, A., Lauber, K., Grunebach, F., Van Parijs, L., Denzlinger, C., Wesselborg, S., and Brossart, P. (2003) Cyclopentenone prostaglandins induce lymphocyte apoptosis by activating the mitochondrial apoptosis pathway independent of external death receptor signaling. J. Immunol. 171, 5148-56.
31. Miki, S., Iwano, M., Miki, Y., Yamamoto, M., Tang, B., Yokokawa, K., Sonoda, T., Hirano, T., and Kishimoto, T. (1989) Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas. FEBS Lett. 250,607-10.
32. Oka, H., Chatani, Y., Hoshino, R., Ogawa, O., Kakehi, Y., Terachi, T., Okada, Y., Kawaichi, M., Kohno, M., and Yoshida, O. (1995) Constitutive activation of mitogen-activated protein (MAP) kinases in human renal cell carcinoma. Cancer Res. 55, 4182-7.
33. Oya, M., Takayanagi, A., Horiguchi, A., Mizuno, R., Ohtsubo, M., Marumo, K., Shimizu, N., and Murai, M. (2003) Increased nuclear factor-kappa B activation is related to the tumor development of renal cell carcinoma. Carcinogenesis. 24, 377-84.
34. Oya, M., Ohtsubo, M., Takayanagi, A., Tachibana, M., Shimizu, N., and Murai, M. (2001) Constitutive activation of nuclear factor-kappaB prevents TRAIL-induced apoptosis in renal cancer cells. Oncogene. 20, 3888-96.
35. Chung, S. W., Kang, B. Y., Kim, S. H., Pak, Y. K., Cho, D., Trinchieri, G., and Kim, T. S. (2000) Oxidized low density lipoprotein inhibits interleukin-12 production in lipopolysaccharide-activated mouse macrophages via direct interactions between peroxisome proliferator-activated receptor-gamma and nuclear factor-kappa B. J. Biol. Chem. 275, 32681-7.
36. Ray, A., and Prefontaine, K. E. (1994) Physical association and functional antagonism between the p65 subunit of transcription factor NF-kappa B and the glucocorticoid receptor. Proc. Natl. Acad. Sci. U. S. A. 91, 752-6.
37. Wan, H., Yuan, Y., Qian, A., Sun, Y., and Qiao, M. (2008) Pioglitazone, a PPARgamma ligand, suppresses NFkappaB activation through inhibition of IkappaB kinase activation in cerulein-treated AR42J cells. Biomed. Pharmacother. 62, 466-72.
38. Liu, M. Y., Poellinger, L., and Walker, C. L. (2003) Upregulation of hypoxia-inducible factor 2alpha in renal cell carcinoma associated with loss of Tsc-2 tumor suppressor gene. Cancer Res. 63, 2675-80.
39. Ellgaard, L. and Helenius, A. (2003) Quality control in the endoplasmic reticulum. Rat. Rev. Mol. Cell. Biol. 4, 181-91.
40. Werner, E. D., Brodsky, J. L., and McCracken, A. A. (1996) Proteasome-dependent endoplasmic reticulum-associated protein degradation: an unconventional route to a familiar fate. Proc. Natl. Acad. Sci. U. S. A. 93, 13797-801.
41. Wang, N., Verna, L., Chen, N. G., Chen, J., Li, H., Forman, B. M., and Stemerman, M. B. (2002) Constitutive activation of peroxisome proliferator-activated receptor-gamma suppresses pro-inflammatory adhesion molecules in human vascular endothelial cells. J. Biol. Chem. 277, 34176-81.
42. Gardner, O. S., Dewar, B. J., Earp, H. S., Samet, J. M., and Graves, L. M. (2003) Dependence of peroxisome proliferator-activated receptor ligand-induced mitogen-activated protein kinase signaling on epidermal growth factor receptor transactivation. J. Biol. Chem. 278, 46261-9.
43. Kim, E. J., Park, K. S., Chung, S. Y., Sheen, Y. Y., Moon, D. C., Song, Y. S., Kim, K. S., Song, S., Yun, Y. P., Lee, M. K., Oh, K. W., Yoon, D. Y., and Hong, J. T. (2003) Peroxisome proliferator-activated receptor-gamma activator 15-deoxy-Delta12,14-prostaglandin J2 inhibits neuroblastoma cell growth through induction of apoptosis: association with extracellular signalregulated kinase signal pathway. J. Pharmacol. Exp. Ther. 307, 505-17.
44. Motomura, W., Tanno, S., Takahashi, N., Nagamine, M., Fukuda, M., Kohgo, Y., and Okumura, T. (2005) Involvement of MEK-ERK signaling pathway in the inhibition of cell growth by troglitazone in human pancreatic cancer cells. Biochem. Biophys. Res. Commun. 332, 89-94.
45. Jung, J. Y., Yoo, C. I., Kim, H. T., Kwon, C. H., Park, J. Y., and Kim, Y. K. (2007) Role of mitogen-activated protein kinase (MAPK) in troglitazone-induced osteoblastic cell death. Toxicology. 234, 73-82.
46. Myers, M. P., Pass, I., Batty, I. H., Van der, K. J., Stolarov, J. P., Hemmings, B. A., Wigler, M. H., Downes, C. P., and Tonks, N. K. (1998) The lipid phosphatase activity of PTEN is critical for its tumor supressor function. Proc. Natl. Acad. Sci. U. S. A. 95, 13513-8.
47. Patel, L., Pass, I., Coxon, P., Downes, C. P., Smith, S. A., and Macphee, C. H. (2001) Tumor suppressor and anti-inflammatory actions of PPARgamma agonists are mediated via upregulation of PTER Curr. Biol. 11, 764-8.
48. Castell, J. V., Gomez-Lechon, M. J., David, M., Fabra, R., Trullenque, R., and Heinrich, P. C. (1990) Acute-phase response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6. Hepatology. 12, 1179-86.
49. Schuringa, J. J., Wierenga, A. T., Kruijer, W., and Vellenga, E. (2000) Constitutive Stat3, Tyr705, and Ser727 phosphorylation in acute myeloid leukemia cells caused by the autocrine secretion of interleukin-6. Blood. 95, 3765-70.
50. Wu, K.L., Miao, H., and Khan, S. (2007) JAK kinases promote invasiveness in VHL-mediated renal cell carcinoma by a suppressor of cytokine signaling-regulated, HIF-independent mechanism. Am. J. Physiol. Renal Physiol. 293, F1836-F1846.
51. Shang, D., Liu, Y., Ito, N., Kamoto, T., and Ogawa, O. (2007) Defective Jak-Stat activation in renal cell carcinoma is associated with interferon-alpha resistance. Cancer Sci. 98, 1259-64.
52. Shinojima, T., Oya, M., Takayanagi, A., Mizuno, R., Shimizu, N., and Murai, M. (2007) Renal cancer cells lacking hypoxia inducible factor (HIF)-1alpha expression maintain vascular endothelial growth factor expression through HIF-2alpha. Carcinogenesis. 28, 529-36.
53. Blay, J. Y., Negrier, S., Combaret, V., Attali, S., Goillot, E., Merrouche, Y., Mercatello, A., Ravault, A., Tourani, J. M., and Moskovtchenko, J. F. (1992) Serum, level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res. 52, 3317-22.
54. Kawano, M., Hirano, T., Matsuda, T., Taga, T., Horii, Y., Iwato, K., Asaoku, H., Tang, B., Tanabe, O., and Tanaka, H. (1988) Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature. 332, 83-5.
55. Ming, M., Yu, J. P., Meng, X. Z., Zhou, Y. H., Yu, H. G., and Luo, H. S. (2006) Effect of ligand troglitazone on peroxisome proliferator-activated receptor gamma expression and cellular growth in human, colon cancer cells. World J. Gastroenterol. 12, 7263-70.
56. Nijhawan, D., Fang, M., Traer, E., Zhong, Q., Gao, W., Du, F., and Wang, X. (2003) Elimination of Mcl-1 is required for the initiation of apoptosis following ultraviolet irradiation. Genes Dev. 17, 1475-86.
57. Parker, A.S., Kosari F., Lohse C. M., Houston, T.R., Kwon, E. D., Murphy, L., Riehle, D. L., Blute, M. L., Leibovich, B.C., Vasmatzis, G., and Cheville, J.C. (2006) High expression levels of survivin protein independently predict a poor outcome for patients who undergo surgery for clear cell renal cell carcinoma. Cancer. 107, 37-45.
58. Tsao, W. C., Wu., H. M., Chi, K. H., Chang, Y.H., and Lin W. W. (2005) Proteasome inhibitors induce peroxisome proliferator-activated receptor transactivation through RXR accumulation and a protein kinase C-dependent pathway. Exp. Cell Res. 304, 234-43.